These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33313384)

  • 41. Nanoparticle-peptide conjugates for bacterial detection and neutralization: Potential applications in diagnostics and therapy.
    Gonçalves S; Martins IC; Santos NC
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Nov; 14(6):e1819. PubMed ID: 36416027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liposome-Based Antibacterial Delivery: An Emergent Approach to Combat Bacterial Infections.
    Ghosh R; De M
    ACS Omega; 2023 Oct; 8(39):35442-35451. PubMed ID: 37810644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Target the Host, Kill the Bug; Targeting Host Respiratory Immunosuppressive Responses as a Novel Strategy to Improve Bacterial Clearance During Lung Infection.
    Kelly AM; McLoughlin RM
    Front Immunol; 2020; 11():767. PubMed ID: 32425944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanomedicines for the Delivery of Antimicrobial Peptides (AMPs).
    Teixeira MC; Carbone C; Sousa MC; Espina M; Garcia ML; Sanchez-Lopez E; Souto EB
    Nanomaterials (Basel); 2020 Mar; 10(3):. PubMed ID: 32244858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging antibacterial nanomedicine for enhanced antibiotic therapy.
    Wang S; Gao Y; Jin Q; Ji J
    Biomater Sci; 2020 Dec; 8(24):6825-6839. PubMed ID: 32996490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial responses of teleost phagocytes and innate immune evasion strategies of intracellular bacteria.
    Grayfer L; Hodgkinson JW; Belosevic M
    Dev Comp Immunol; 2014 Apr; 43(2):223-42. PubMed ID: 23954721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: research progress, challenges, and prospects.
    Mba IE; Nweze EI
    World J Microbiol Biotechnol; 2021 May; 37(6):108. PubMed ID: 34046779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advances in sepsis diagnosis and management: a paradigm shift towards nanotechnology.
    Pant A; Mackraj I; Govender T
    J Biomed Sci; 2021 Jan; 28(1):6. PubMed ID: 33413364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pore-forming toxins of foodborne pathogens.
    Banerji R; Karkee A; Kanojiya P; Saroj SD
    Compr Rev Food Sci Food Saf; 2021 May; 20(3):2265-2285. PubMed ID: 33773026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of Antibodies and Antibiotics as a Promising Strategy Against Multidrug-Resistant Pathogens of the Respiratory Tract.
    Domenech M; Sempere J; de Miguel S; Yuste J
    Front Immunol; 2018; 9():2700. PubMed ID: 30515172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review on anti-adhesion therapies of bacterial diseases.
    Asadi A; Razavi S; Talebi M; Gholami M
    Infection; 2019 Feb; 47(1):13-23. PubMed ID: 30276540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-Kingdom Infection of Macrophages Reveals Pathogen- and Immune-Specific Global Reprogramming and Adaptation.
    Sukumaran A; Ball B; Krieger JR; Geddes-McAlister J
    mBio; 2022 Aug; 13(4):e0168722. PubMed ID: 35862772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Engineering Cell Membrane-Based Nanotherapeutics to Target Inflammation.
    Yan H; Shao D; Lao YH; Li M; Hu H; Leong KW
    Adv Sci (Weinh); 2019 Aug; 6(15):1900605. PubMed ID: 31406672
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breaking antimicrobial resistance by disrupting extracytoplasmic protein folding.
    Furniss RCD; Kaderabkova N; Barker D; Bernal P; Maslova E; Antwi AAA; McNeil HE; Pugh HL; Dortet L; Blair JMA; Larrouy-Maumus G; McCarthy RR; Gonzalez D; Mavridou DAI
    Elife; 2022 Jan; 11():. PubMed ID: 35025730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal.
    Tarín-Pelló A; Suay-García B; Pérez-Gracia MT
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1095-1108. PubMed ID: 35576494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in
    Cerni S; Shafer D; To K; Venketaraman V
    J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30754665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Metabokines reviewed: Essential mediators of anti-infectious immunity].
    Cezard A; Monard S; Bréa-Diakite D; Guillon A; Si-Tahar M
    Med Sci (Paris); 2021 Apr; 37(4):342-348. PubMed ID: 33908851
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.